Sign in
Not yet taking people in FrancePhase 1/2

Gene therapy tested in children with spinal muscular atrophy and progressive myoclonic epilepsy

Tests a gene therapy given into the spinal fluid of children with SMA-PME.

Key facts

Who runs it
Genethon
Where
Le Kremlin Bicetre Cedex and Paris, FranceSee the 2 sites
Registry title
AAV9-ASAH1 intracisterna magna Gene Therapy (GNT0009) in Patients with Spinal Muscular Atrophy with Progressive Myoclonic Epilepsy (SMA - PME)
Status
Not yet recruiting
Phase
Phase 1/2
People taking part
3 people, planned
Started
16 Nov 2026
Expected to end
16 Nov 2031
Type of study
Interventional
Record updated
9 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with a genetically confirmed diagnosis of spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME). They receive a single gene therapy dose into the fluid space at the base of the brain.

Age
Up to 17 years.
Sex
Males and females can join.
Disease stage
Genetically documented SMA-PME. People who have lost all movement and all head and trunk control cannot join.
Earlier treatment
Vaccinations must be up to date under the French national schedule (2025). Strong CYP3A4 or P-gp inducer or inhibitor medicines cannot be used at the same time.
Biomarker or test result
A documented genetic diagnosis of SMA-PME is needed.

Main reasons for not taking part

  • Farber disease
  • HIV infection, or active hepatitis B or hepatitis C infection
  • Severe intellectual disability (for example IQ below 50)
  • Severe breathing problems (for example FVC below 30% predicted, or long-term ventilation)
  • Raised pressure in the head, hydrocephalus, or a bleeding risk from clotting problems

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Male or female participants
  • Documented genetically SMA-PME diagnosis
  • Up-to-date immunization status according to the French national vaccination schedule (2025), including recommended vaccines for age and/or risk groups, notably: hepatitis B, measles-mumps-rubella (MMR), varicella*, hepatitis A (in at-risk populations), Neisseria meningitidis (ACWY + B), Streptococcus pneumoniae, seasonal influenza, SARS-CoV-2, and respiratory syncytial virus (RSV) where indicated
  • Ability of the participant and/or legal representatives to confirm the adherence to the clinical trial visit schedule and all protocol requirements
  • Effective contraception

Who cannot take part

  • Concomitant use of strong CYP3A4 and/or P-glycoprotein (P-gp) inducers or inhibitors
  • Presence of any permanent or non-MRI–compatible implants or devices (e.g., metal braces) that preclude safe MRI assessment
  • Diagnosis of Farber disease
  • Positive serology consistent with human immunodeficiency virus (HIV) infection or evidence of active hepatitis B or hepatitis C infection
  • Severely impaired pulmonary function (e.g., FVC <30% predicted) and/or respiratory insufficiency requiring either of the following: (a) non-invasive ventilation for >16 hours per day, or (b) invasive mechanical ventilation via tracheostomy
  • Coagulation disorders or clinically significant abnormalities in coagulation parameters that increase the risk of bleeding associated with ICM administration
  • Presence of a severe concomitant medical condition or clinically significant abnormal laboratory / imaging findings that, in the opinion of the investigator, may interfere with the course of SMA-PME or place the participant at increased risk of severe complications
  • Severe intellectual disability (e.g., intellectual quotient [IQ] < 50)
  • Gross Motor Function Classification in Metachromatic Leukodystrophy (GMFC-MLD) score of 6 (loss of any locomotion as well as loss of any head and trunk control)
  • Hepatic dysfunction Grade ≥3 as defined by CTCAE criteria
  • History or evidence of increased intracranial pressure, hydrocephalus, or need for CSF diversion

Where in France

  • Bicetre HospitalLe Kremlin Bicetre Cedex, FranceNot yet recruiting
  • Trousseau HospitalParis, FranceNot yet recruiting

About the trial

What the trial wants to find out

To evaluate the safety and tolerability of a single ICM administration of GNT0009 in patients with SMA-PME

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Phase 1/2 Open-Label Trial to Evaluate the Safety, Tolerability, Biological Activity, and Clinical Efficacy of intracisterna Magna administration of an AAV9 Vector Encoding Human ASAH1 (GNT0009) in Patients with Spinal Muscular Atrophy with Progressive Myoclonic Epilepsy (SMA-PME)
Plain-language title
Gene therapy tested in children with spinal muscular atrophy and progressive myoclonic epilepsyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
9 November 2026